source
- Vir Biotechnology signs $65M upfront deal with Gilead for solid tumor T-cell engagerVir Biotechnology announced a new collaboration with Gilead Sciences focused on a solid tumor T-cell engager. Under the agreement, Gilead will provide an upfront payment of $65 million and up to $…
- Arrowhead’s RNA drug cuts Alzheimer’s tau protein in early human studyArrowhead Pharmaceuticals reported early-stage data showing its subcutaneous RNA therapeutic can reach the brain and lower tau protein, a hallmark of Alzheimer’s disease. In a first-in-human trial…